EPIRUS Biopharmaceuticals Reports First Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
EPIRUS Biopharma (EPRS) Tops Q1 EPS by 4c
May 12, 2015 7:12 AM EDTEPIRUS Biopharma (NASDAQ: EPRS) reported Q1 EPS of ($0.39), $0.04 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $25 thousand versus the consensus estimate of $700 thousand.
For earnings history and earnings-related data on EPIRUS Biopharma (EPRS) click here.
... More